Literature DB >> 7793180

Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis.

F S Jensen1, L T Skovgaard, J Viby-Mogensen.   

Abstract

In 1973, a Cholinesterase Research Unit was established in Denmark (DCRU). The primary aim was to provide a central service for determining genotypes and activity of plasma cholinesterase (BChE) in patients showing abnormal response after succinylcholine. The purpose of the present study was, on the basis of 20 years experience with this Unit, to establish accurate reference intervals for BChE activity and inhibition values for the different genotypes of BChE. Also we wanted to evaluate the influence of age and sex on the BChE activity in genotypically normal patients. Plasma cholinesterase activity was measured using benzoylcholine as substrate. The genetic variations of the enzyme were identified using differential inhibitors, i.e.: Dibucaine, Sodium Fluoride, Succinylcholine, Urea and Ro-2-0683. We investigated 6,688 patients. The reference values for the 13 genotypes represented agree with previous findings. In genotypically normal patients, no age or sex differences were found in BChE activity in children below the age of 10 years. From the age of 10 years the activity decreased significantly in both males and females, the activity in females being significantly lower than in males. In females the activity was lowest in the age group 30-40 years, returning to prepuberty level at about 60 years of age. In males the activity decreased slightly up to 50-60 years of age. Hereafter the activity was stable or tended to increase slightly. Most genotypes could be recognized using the results of the different inhibition studies. We found the inhibitors Dibucaine, Sodium fluoride, Urea and Ro-2-0683 most helpful, whereas succinylcholine was of less value.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793180     DOI: 10.1111/j.1399-6576.1995.tb04035.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  9 in total

1.  Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.

Authors:  Niklas Lindegardh; Geraint R Davies; Tinh Hien Tran; Jeremy Farrar; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors.

Authors:  Beben Benyamin; Rita P Middelberg; Penelope A Lind; Anne M Valle; Scott Gordon; Dale R Nyholt; Sarah E Medland; Anjali K Henders; Andrew C Heath; Pamela A F Madden; Peter M Visscher; Daniel T O'Connor; Grant W Montgomery; Nicholas G Martin; John B Whitfield
Journal:  Hum Mol Genet       Date:  2011-08-23       Impact factor: 6.150

3.  Interaction between mivacurium and pancuronium: impact of the order of administration.

Authors:  C Motamed; K Kirov; X Combes; P Feiss; P Duvaldestin
Journal:  Eur J Clin Pharmacol       Date:  2005-04-12       Impact factor: 2.953

4.  Black and non-black population: investigation of the difference in butyrylcholinesterase activity in a healthy population in Salvador, Bahia.

Authors:  Jucelino Nery da Conceição Filho; Iris Campos Dos Santos; Davi Pereira de Jesus Gonçalves; Junia Raquel Dutra Ferreira; Ana Leonor Pardo Campos Godoy
Journal:  Ir J Med Sci       Date:  2022-07-06       Impact factor: 1.568

5.  Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine.

Authors:  Guang-Dan Zhu; Eric Dawson; Angela Huskey; Ronald J Gordon; Andria L Del Tredici
Journal:  Pharmgenomics Pers Med       Date:  2020-09-30

6.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

7.  Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population.

Authors:  Melih O Babaoglu; Turgay Ocal; Banu Bayar; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-01-21       Impact factor: 2.953

8.  Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase.

Authors:  U Bang; L Nyberg; J Rosenborg; J Viby-Mogensen
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

9.  Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers.

Authors:  Margherita Strolin Benedetti; Rhys Whomsley; Jean-Marie Nicolas; Colin Young; Eugène Baltes
Journal:  Eur J Clin Pharmacol       Date:  2003-10-07       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.